Ardelyx - ARDX Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.

6 brokerages have issued 1-year price targets for Ardelyx's shares. Their ARDX share price forecasts range from $1.00 to $10.00. On average, they expect the company's stock price to reach $4.33 in the next twelve months. This suggests a possible upside of 283.5% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.

Ardelyx's stock was trading at $1.10 at the beginning of 2022. Since then, ARDX shares have increased by 2.7% and is now trading at $1.13.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our ARDX earnings forecast.

Ardelyx, Inc. (NASDAQ:ARDX) announced its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, meeting analysts' consensus estimates of ($0.19). The biopharmaceutical company had revenue of $2.53 million for the quarter, compared to the consensus estimate of $0.62 million. Ardelyx had a negative trailing twelve-month return on equity of 191.74% and a negative net margin of 2,594.88%. During the same period in the prior year, the company earned ($0.45) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (3.23%), Prosight Management LP (1.40%), Ikarian Capital LLC (1.09%), Millennium Management LLC (1.00%), Sio Capital Management LLC (0.45%) and State Street Corp (0.31%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends.

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $1.13.

Ardelyx (NASDAQ:ARDX) has a market capitalization of $174.74 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158,160,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.